Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-02-10 / Cancer Immunol. Immunother. 2016 Mar;65(3):327-39Novel immunotherapeutic approaches to the treatment of urothelial carcinoma
/in Dendritic Cells, International Publications, Newcastle Disease Virus, Urothelial Carcinoma /von 2016-02-09 / Ther Adv Urol 2016 Jun;8(3):203-14IOZK Beitrag in der Fachzeitschrift für Orthomolekulare Medizin, Sonderheft: Onkologie
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKType I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-02-01 / Melanoma Res. 2016 Feb;26(1):1-11
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution